Nav: Home

Electronic reminders can help tuberculosis patients stay on medication

September 15, 2015

Reminders to take medication, delivered to patients via an electronic pillbox, may be able to improve adherence to tuberculosis (TB) treatment. The findings, reported this week in PLOS Medicine, are the result of a cluster randomized controlled trial by Shiwen Jiang of the Chinese Centers for Disease Control & Prevention, Katherine Fielding, of the London School of Hygiene & Tropical Medicine, and colleagues.

The study randomized 36 districts in the provinces of Heilongjiang, Jiangsu, Hunan, and Chongqing, China to receive one of four approaches to tuberculosis case management: medication reminders via text messages (1008 patients), a medication monitor box (997 patients), both (1064 patients), or neither (control, 1104 patients). Medication adherence for the 4173 TB patients included in the study was monitored by pill counts and the medication monitor box (supplied to all patients but only providing reminders to the appropriate intervention groups).

While patients in the control arm were non-adherent (percentage of patient-months with more than 20% of their doses missed) in 29.9% of the months, patients who received reminders from the medication box were non-adherent in 17.0% of the months, and in only 13.9% of months for patients who received reminders via both the medication box and text message. There was no significant difference from control arm for patients receiving text message reminders only. The researchers noted that there were difficulties with the equipment in all arms, including operator error and equipment malfunctions.

In an accompanying Perspective article, John Metcalfe of the University of California San Francisco and colleagues discuss the importance of adherence to TB medication, difficulties with the traditional method of ensuring adherence through directly observed treatment (DOT), and the importance of developing effective new methods that reduce burden to patients and are easier to implement at a large scales and in remote areas.

Metcalfe and colleagues say: "If replicated, [this study] will have important implications for global TB treatment in moving away from witnessed dosing, which is not universally feasible, towards a more personalized adherence model of patient-provider communication in which intervention is delivered where, when, and in whom it is needed to efficiently prevent adverse treatment outcome."

Fielding and colleagues say: "In a setting such as China where universal use of DOT is not feasible, innovative approaches to enable patients to adhere to TB treatment are needed. Widespread use of medication monitors in national TB control programs can benefit from the development of a low-cost and reliable medication monitor as well as evidence that its use can improve clinical outcomes."
-end-
Research Article

Funding: The study was funded by the Bill & Melinda Gates Foundation, grant number 51914 (http://www.gatesfoundation.org/). The funders (DPC, SH) contributed to design, running of the trial, and preparation of manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. (2015) Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med 12(9): e1001876. doi:10.1371/journal.pmed.1001876

Author Affiliations:

National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
MRC Tropical Epidemiology Group, London School of Hygiene & Tropical Medicine, London, United Kingdom
Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu, China
Chongqing Provincial Tuberculosis Dispensary, Chongqing, Chongqing, China
Heilongjiang Provincial Tuberculosis Dispensary, Harbin, Heilongjiang, China
Hunan Provincial Tuberculosis Dispensary, Changsha, Hunan, China
Dafeng County Center for Disease Control and Prevention, Dafeng, Jiangsu, China
China Office, Bill & Melinda Gates Foundation, Beijing, China

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001876

Contact:
The London School of Hygiene & Tropical Medicine
press@lshtm.ac.uk
+44(0)2079272802

Perspective Article

Funding: No specific funding.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Metcalfe JZ, O'Donnell MR, Bangsberg DR (2015) Moving Beyond Directly Observed Therapy for Tuberculosis. PLoS Med 12(9): e1001877. doi:10.1371/journal.pmed.1001877

Author Affiliations:

Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America
Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York, New York, United States of America
Massachusetts General Hospital, Harvard Medical School, Harvard School of Public Health, Boston, Massachusetts, United States of America
Mbarara University of Science and Technology, Mbarara, Uganda

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001877

PLOS

Related Tuberculosis Articles:

Blocking the iron transport could stop tuberculosis
The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply.
Tuberculosis: New insights into the pathogen
Researchers at the University of Würzburg and the Spanish Cancer Research Centre have gained new insights into the pathogen that causes tuberculosis.
Unmasking the hidden burden of tuberculosis in Mozambique
The real burden of tuberculosis is probably higher than estimated, according to a study on samples from autopsies performed in a Mozambican hospital.
HIV/tuberculosis co-infection: Tunneling towards better diagnosis
1.2 million people in the world are co-infected by the bacteria which causes tuberculosis and AIDS.
Reducing the burden of tuberculosis treatment
A research team led by MIT has developed a device that can lodge in the stomach and deliver antibiotics to treat tuberculosis, which they hope will make it easier to cure more patients and reduce health care costs.
Tuberculosis: Commandeering a bacterial 'suicide' mechanism
The bacteria responsible for tuberculosis can be killed by a toxin they produce unless it is neutralized by an antidote protein.
A copper bullet for tuberculosis
Tuberculosis is a sneaky disease, and the number one cause of death from infectious disease worldwide.
How damaging immune cells develop during tuberculosis
Insights into how harmful white blood cells form during tuberculosis infection point to novel targets for pharmacological interventions, according to a study published in the open-access journal PLOS Pathogens by Valentina Guerrini and Maria Laura Gennaro of Rutgers New Jersey Medical School, and colleagues.
How many people die from tuberculosis every year?
The estimates for global tuberculosis deaths by the World Health Organisation (WHO) and the Institute for Health Metrics and Evaluation (IHME) differ considerably for a dozen countries, according to a study led by ISGlobal.
Beyond killing tuberculosis
Historically, our view of host defense against infection was that we must eliminate pathogens to eradicate disease.
More Tuberculosis News and Tuberculosis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: Reinvention
Change is hard, but it's also an opportunity to discover and reimagine what you thought you knew. From our economy, to music, to even ourselves–this hour TED speakers explore the power of reinvention. Guests include OK Go lead singer Damian Kulash Jr., former college gymnastics coach Valorie Kondos Field, Stockton Mayor Michael Tubbs, and entrepreneur Nick Hanauer.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Dispatch 6: Strange Times
Covid has disrupted the most basic routines of our days and nights. But in the middle of a conversation about how to fight the virus, we find a place impervious to the stalled plans and frenetic demands of the outside world. It's a very different kind of front line, where urgent work means moving slow, and time is marked out in tiny pre-planned steps. Then, on a walk through the woods, we consider how the tempo of our lives affects our minds and discover how the beats of biology shape our bodies. This episode was produced with help from Molly Webster and Tracie Hunte. Support Radiolab today at Radiolab.org/donate.